About us Pricing ContactSubscribe

J

Johannes Ettl

Technical University of MunichORCID https://orcid.org/0000-0003-4754-8447

h-index

—

Publications

—

Citations

—

i10-index

—

Impact (2-yr)

—

Top Publications

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

The Lancet Oncology20141,891 citations

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Breast Cancer Research and Treatment2019426 citations

Johannes Ettl · Scinovex